Dramatic advances in the fields of biochemistry, cell and molecular biology, genetics, biomedical engineering and materials science have given rise to the remarkable new cross-disciplinary field of tissue engineering. Tissue engineering uses synthetic or naturally derived, engineered biomaterials to replace damaged or defective tissues, such as bone, skin, and even organs.
In a medical breakthrough, researchers have been able to convert skin cells into liver cells. This could one day eliminate the need for organ transplants, they say.
Disorders of the eye are excellent targets for gene therapy because the ocular environment is readily accessible, relatively easy to monitor, and sequestered from the rest of the body.
Researchers at Columbia Engineering have established a new method to patch a damaged heart using a tissue-engineering platform that enables heart tissue to repair itself.
InVivo Therapeutics, a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries, and The University of Miami Miller School of Medicine's Miami Project to Cure Paralysis, the world's most comprehensive spinal cord injury research center, today announced a strategic research collaboration for the development of novel SCI treatments.
The University of Virginia and the Wallace H. Coulter Foundation have teamed to create a $20 million endowment to foster research collaboration between biomedical engineers and clinicians, with the goal of developing new technologies to improve patient care and human health.
A team of bioengineers from Rice University is bringing a promising new strategy for growing replacement heart valves closer to reality, thanks to a four-year, $1.2 million grant from the National Institutes of Health. The team hopes to use gel-like materials to generate three-dimensional patterns called scaffolds that can simultaneously mimic the complex structural and physical properties of heart-valve tissues and guide the behavior of tissue-forming cells.
Researchers extracted pig corneal cells and replaced them with human stem cells. Thus, the University of Granada takes the lead in the making of bioartificial organs, a field so far led by the Hospital Gregorio Marañón in Madrid.
In the first study investigating the origins of a little-known condition called chronic ulcerative stomatitis, researchers at Tufts University School of Dental Medicine provide evidence that an autoimmune response contributes to the painful oral sores that characterize the disease. The study findings support the classification of CUS as a new autoimmune disease.
BioLife Solutions, Inc., a leading developer and manufacturer of clinical grade biopreservation media products for cells and tissues, today announced preliminary revenue of $611,000 for its first quarter ended March 31, 2011.
Scientists at Polytechnic Institute of New York University (NYU-Poly) and at the NYU College of Dentistry have discovered a biochemical version of a principle well known among confectioners. Call it the "peanut butter and chocolate" rule: Sometimes two things work better together than alone.
BioCer Entwicklungs GmbH, a Bayreuth, Germany based medical device manufacturer, has announced their attendance at the China Medical Equipment Fair (CMEF) Shenzhen, China 15th-19th April 2011. HaemoCer™ an Absorbable Polysaccharide Hemostat (APH) and Ti0²Mesh™ Hernia repair system will be on exhibit at the BioCer booth.
Arthritis researchers from North America and Europe will convene in Chicago this week to present new osteoarthritis research that could lead to better ways to detect, treat, prevent and cure osteoarthritis, which affects 27 million Americans.
At present, cartilage implants created using stem cells can only be constructed as a solid shape, acting as an interim measure before the almost inevitable need for total joint replacement.
Minute whiskers of nanoscale dimensions taken from sea creatures could hold the key to creating working human muscle tissue, University of Manchester researchers have discovered.
In a scientific breakthrough, five boys who were unable to urinate due to pelvic injury were cured for up to six years after getting new lab-grown urethras or urinary tubes that connect with the bladder. This breakthrough comes from Wake Forest University researcher Anthony Atala. It was in 2006 that the team reported the first successful implantation of lab-grown urinary bladders into humans. Today six years after the operation all of the boys continue to do well, with normal or near-normal urinary flow. The boy first treated is now 16 years old and received his lab-grown urethra over six years ago.
Researchers at the Institute for Regenerative Medicine at Wake Forest University Baptist Medical Center and colleagues reported today on a new advance in tissue engineering.
Biologists tend to look at cells in bulk, observing them as a group and taking the average behavior as the norm - the assumption is that genetically identical cells all behave the same way.
Transplanting stem cells derived from umbilical cord blood cells and menstrual blood cells may offer future therapeutic benefit for those suffering from stroke, Alzheimer's disease, and amyotrophic lateral sclerosis, says a team of neuroscience researchers from the University of South Florida's Department of Neurosurgery and Brain Repair and collaborators from three private-sector research groups, Saneron CCEL Therapeutics, Inc., Tampa, FL, Cryo-Cell International, Inc., Oldsmar, FL, and Cryopraxis, Cell Praxis, BioRio, Rio de Janeiro, Brazil.
In what seems like science fiction, Dr. Anthony Atala, a regenerative medicine specialist at Wake Forest University, is pioneering the use of printing techniques to reconstruct and repair human flesh and organs. His basis is a combination of cultured human cells and scaffolding built or woven from organic material.
Yissum Research Development Company Ltd., the technology transfer company of the Hebrew University of Jerusalem, and Hadasit Medical Research Services & Development Ltd., the technology transfer company of the Hadassah University Medical Center, today announced that they have licensed innovative regenerative membrane implant technology to RegeneCure, which will further develop and commercialize the technology for bone tissue engineering for applications in trauma, spine, and reconstructive cranial and facial orthopedics.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.